Bristol-Myers Squibb and Johnson & Johnson announced FDA-approval of Evotaz and Prezcobix, combination HIV-1 infection treatments.
On Jan. 29, 2015, Bristol-Myers Squibb (BMS) and Johnson & Johnson (J&J) both announced FDA approval of HIV treatments. BMS announced the approval of Evotaz (atazanavir and cobicistat) when combined with other antiretroviral agents for the treatment of the HIV-1 in adults. On the same day, J&J announced the approval of Prezcobix (darunavir and cobicistat) tablets when combined with other antiretroviral agents.
Both treatments are a once-daily tablet containing a pharmacokinetic enhancer called cobicistat produced by Gilead Sciences, however, Evotaz is combined with the protease inhibitor Reyataz (atazanavir), while Prezcobix uses the protease inhibitor darunavir. The treatments are meant for patients who have not experienced any baseline resistance to the components within the treatments.
Sources:
Bristol-Myers Squibb
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.